Patents Assigned to NAHLS CORPORATION CO., LTD.
  • Publication number: 20220135603
    Abstract: A novel compound has pharmacological activities comparable to those of Nahlsgen and is storable excellently stably. The compound can be produced by a method according to the present invention for producing an optically active 2-amino-phosphonoalkanoic acid salt. In the method, a starting material DL-2-amino-phosphonoalkanoic acid represented by Formula (1) or a hydrate thereof is reacted with an optically active basic compound other than an optically active lysine, to give a diastereomeric salt mixture including a first salt (including a hydrate salt) between a D-2-amino-phosphonoalkanoic acid represented by Formula (1-1) and the optically active basic compound, and a second salt (including a hydrate salt) between an L-2-amino-phosphonoalkanoic acid represented by Formula (1-2) and the optically active basic compound. The diastereomeric salt mixture is fractionally crystallized to isolate one of the first and second diastereomeric salts.
    Type: Application
    Filed: November 19, 2021
    Publication date: May 5, 2022
    Applicants: NAHLS CORPORATION CO., LTD., KYOTO UNIVERSITY
    Inventors: Bunta WATANABE, Ryuzo Yoshioka, Hideaki Ishida
  • Patent number: 11220521
    Abstract: A novel compound has pharmacological activities comparable to those of Nahlsgen and is storable excellently stably. The compound can be produced by a method according to the present invention for producing an optically active 2-amino-phosphonoalkanoic acid salt. In the method, a starting material DL-2-amino-phosphonoalkanoic acid represented by Formula (1) or a hydrate thereof is reacted with an optically active basic compound other than an optically active lysine, to give a diastereomeric salt mixture including a first salt (including a hydrate salt) between a D-2-amino-phosphonoalkanoic acid represented by Formula (1-1) and the optically active basic compound, and a second salt (including a hydrate salt) between an L-2-amino-phosphonoalkanoic acid represented by Formula (1-2) and the optically active basic compound. The diastereomeric salt mixture is fractionally crystallized to isolate one of the first and second diastereomeric salts.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: January 11, 2022
    Assignees: NAHLS CORPORATION CO., LTD., KYOTO UNIVERSITY
    Inventors: Bunta Watanabe, Ryuzo Yoshioka, Hideaki Ishida
  • Patent number: 10774098
    Abstract: Provided is a method for separating the four optical isomers of Nahlsgen.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: September 15, 2020
    Assignees: KYOTO UNIVERSITY, NAHLS CORPORATION CO., LTD.
    Inventors: Jun Hiratake, Bunta Watanabe, Ryuzo Yoshioka, Hideaki Ishida
  • Publication number: 20200131207
    Abstract: A novel compound has pharmacological activities comparable to those of Nahlsgen and is storable excellently stably. The compound can be produced by a method according to the present invention for producing an optically active 2-amino-phosphonoalkanoic acid salt. In the method, a starting material DL-2-amino-phosphonoalkanoic acid represented by Formula (1) or a hydrate thereof is reacted with an optically active basic compound other than an optically active lysine, to give a diastereomeric salt mixture including a first salt (including a hydrate salt) between a D-2-amino-phosphonoalkanoic acid represented by Formula (1-1) and the optically active basic compound, and a second salt (including a hydrate salt) between an L-2-amino-phosphonoalkanoic acid represented by Formula (1-2) and the optically active basic compound. The diastereomeric salt mixture is fractionally crystallized to isolate one of the first and second diastereomeric salts.
    Type: Application
    Filed: April 13, 2018
    Publication date: April 30, 2020
    Applicants: NAHLS CORPORATION CO., LTD., KYOTO UNIVERSITY
    Inventors: Bunta WATANABE, Ryuzo YOSHIOKA, Hideaki ISHIDA
  • Publication number: 20200121700
    Abstract: A pharmaceutical preparation efficaciously promotes tissue wound repair. The wound repair promoter according to the present invention includes at least one active ingredient selected from the group consisting of compounds represented by Formula (1), salts of the compounds, and hydrates of the compounds or the salts. In the formula, R1 and R2 are each, identically or differently, selected from hydrogen and a hydrocarbon group optionally having one or more substituents selected from the group consisting of halogens, —COOR3, —CONR32, —COR3, —CN, —NO2, —NHCOR3, —OR3, —SR3, —OCOR3, —SO3R3, and —SO2NR32, where R3 is, identically or differently in each occurrence, selected from hydrogen and an optionally substituted aliphatic hydrocarbon group; and n represents an integer of 1 or more.
    Type: Application
    Filed: April 13, 2018
    Publication date: April 23, 2020
    Applicants: NAHLS CORPORATION CO., LTD., NIHON UNIVERSITY, RIKEN
    Inventors: Ryuzo YOSHIOKA, Yoko TANAKA, Manabu YAGUCHI, Takashi TANAKA